Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillinsusceptible or - resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 8, 1997, Pages 1662-1667

  Entenza, J M ^a   Vouillamoz, J ^a   Glauser, M P ^a   Moreillon, P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; FLUCLOXACILLIN; LEVOFLOXACIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL ENDOCARDITIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; INFUSION PUMP; INTRAVENOUS DRUG ADMINISTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS AUREUS;

EID: 0030795382     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.8.1662     Document Type: Article

References (26)

1. Blouin, R. A., L. A. Bauer, D. D. Miller, K. E. Record, and W. O. Griffen. 1982. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob. Agents Chemother. 21:575-580.
2. Borner, K., G. Höffken, H. Lode, P. Koeppe, C. Prinzing, P. Glatzel, R. Wiley, P. Olschewski, B. Sievers, and D. Reinitz. 1986. Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur. J. Clin. Microbiol. 5:179-186.
3. Davis, R., and H. M. Bryson. 1994. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47:677-700.
4. Dholakia, N., K. V. Rolston, D. D. Ho, B. LeBlanc, and G. P. Bodey. 1994. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Antimicrob. Agents Chemother. 38:848-852.
5. Entenza, J. M., J. Vouillamoz, M. Giddey, M. P. Glauser, and P. Moreillon. 1996. Levofloxacin for treatment of experimental endocarditis due to methicillin-susceptible Staphylococcus aureus, abstr. B7, p. 22. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
6. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558.
7. Flückiger, U., P. Francioli, J. Blaser, M. P. Glauser, and P. Moreillon. 1994. Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci. J. Infect. Dis. 169:1397-1400.
8. Francioli, P., J. Etienne, R. Hoigné, J. P. Thys, and A. Gerber. 1992. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. JAMA 267:264-267.
9. Francioli, P., W. Ruch, D. Stamboulian, and the International Infective Endocarditis Study Group. 1995. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin. Infect. Dis. 21:1406-1410.
10. Frank, U., E. Schmidt-Eisenlohr, V. Schlosser, G. Spillner, M. Schindler, and F. D. Daschner. 1988. Concentrations of flucloxacillin in heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgery. Antimicrob. Agents Chemother. 32:930-931.
11. Fu, K. P., S. C. Lafredo, B. Foleno, D. M. Isaacson, J. F. Barret, A. J. Tobia, and M. E. Rosenthale. 1992. In vitro and in vivo antibacterial activities of levofloxacin (L-ofloxacin) an optically active ofloxacin. Antimicrob. Agents Chemother. 36:860-866.
12. Goodwin, S. D., H. A. Gallis, A. T. Chow, F. A. Wong, S. C. Flor, and J. A. Barlett. 1994. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 38:799-804.
13. Hayakawa, I., S. Atarashi, S. Yokohama, M. Imamura, K. Sakano, and M. Furuyawa. 1986. Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob. Agents Chemother. 29:163-164.
14. Heraief, E., M. P. Glauser, and L. Freedman. 1982. Natural history of aortic valve endocarditis in rats. Infect. Immun. 37:127-131.
15. National Committee for Clinical Laboratory Standards. 1992. Methodology for the serum bactericidal test. Tentative standard M21-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
16. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
17. Odio, C., G. H. McCracken, and J. D. Nelson. 1984. Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children. J. Pediatr. 105:491-493.
18. Piddock, L. J. 1994. New quinolones and gram-positive bacteria. Antimicrob. Agents Chemother. 38:163-169.
19. Piercy, E. A., D. Barbaro, J. P. Luby, and P. A. Mackowiak. 1989. Ciprofloxacin for methicillin-resistant Staphylococcus aureus infections. Antimicrob. Agents Chemother. 33:128-130.
20. Sanders, C. C., W. E. Sanders, Jr., and K. S. Thomson. 1995. Fluoroquinolone resistance in staphylococci: new challenges. Eur. J. Clin. Microbiol. Infect. Dis. 14(Suppl. 1):6-11.
21. Sanders, W. E. 1988. Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections. Rev. Infect. Dis. 10:528-543.
22. Stein, G. E. 1996. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin. Infect. Dis. 23(Suppl. 1):S19-S24.
23. Takenouchi, T., C. Ishii, M. Sugawara, Y. Tokue, and S. Ohya. 1995. Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob. Agents Chemother. 39:1414-1418.
24. Une, T., T. Fujimoto, K. Sato, and Y. Osada. 1988. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob. Agents Chemother. 32: 1336-1340.
25. Wilson, W. R., A. W. Karchmer, A. S. Dajani, K. A. Taubert, A. Bayer, D. Kaye, A. L. Bisno, S. T. Shulman, and D. T. Durack. 1995. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. JAMA 274:1706-1713.
26. Yoshida, H., M. Bogaki, S. Nakamura, K. Ubukata, and M. Konno. 1990. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J. Bacteriol. 172:6942-6949.